Naoya Suematsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Naoya Suematsu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Manae Suzuki Kurokawa
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan
4 shared publications - Mitsumi Arito
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan
4 shared publications - Kazuki Okamoto
Institute of Science Tokyo
3 shared publications - Kazuki Omoteyama
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan
3 shared publications - Atsuhiro Tsutiya
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki 216-8511, Kanagawa, Japan
2 shared publications Kazuki Omoteyama
Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, Kawasaki, Japan
2 shared publications
Latest Publications
- 6 August 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 779, 152458
Proximity-dependent biotin identification (BioID) screening identified novel layilin-proximal proteins
- 6 August 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 779, 152458
Proximity-dependent biotin identification (BioID) screening identified novel layilin-proximal proteins
- 14 February 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (9) , 1051-1063
Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes
Background In universal hepatitis B (HB) vaccination, single vaccine-derived polyclonal anti-HBs antibodies (anti-HBs) need to inhibit infection of HB viruses (HBV) of non-vaccine genotypes. We experimentally addressed this issue. Methods Anti-HBs-positive sera were obtained by vaccination with genotype A- or C-derived HBs antigen (HBsAg, gtA-sera or gtC-sera). Their reactivity to genotype A- and C-derived HBsAg (gtA-Ag and gtC-Ag) was measured by ELISA. The capacity of sera to neutralize HBV was evaluated using an in vitro infection model. Results Of 135 anti-gtA-Ag-reactive gtA-sera, 134 (99.3%) were anti-gtC-Ag-reactive. All (100%) 120 anti-gtC-Ag-reactive gtC-sera were anti-gtA-Ag-reactive. The reactivity to gtA-Ag was strongly correlated with that to gtC-Ag (gtA-sera, ρ = 0.989; gtC-sera, ρ = 0.953; p < 0.01). In gtA-sera (n = 10), anti-HBs to gtA-Ag were less completely absorbed with gtC-Ag (96.4%) than with gtA-Ag (100%, p < 0.05). Similarly, in gtC-sera (n = 10), anti-HBs to gtC-Ag were less completely absorbed with gtA-Ag (96.0%) than with gtC-Ag (100%, p < 0.01). Thus, 3.6 and 4.0% of anti-HBs in gtA-sera and gtC-sera were vaccine genotype HBsAg-specific, respectively. In the neutralization test, gtA-sera (n = 4) and gtC-sera (n = 3) with anti-HBs titers adjusted to 100 mIU/mL equally inhibited genotype C HBV infection (92.8 vs. 95.4%, p = 0.44). However, at 30 mIU/mL, the gtA-sera less effectively inhibited infection than the gtC-sera (60.2 vs. 90.2%, p < 0.05). Conclusions Vaccination with genotype A- or C-derived HBsAg provided polyclonal anti-HBs that sufficiently bound to non-vaccine genotype HBsAg. However, a small portion of anti-HBs were specific to the vaccine genotype HBsAg. High anti-HBs titers would be required to prevent HBV infection of non-vaccine genotypes. UMIN/CTR UMIN000014363.
- 14 February 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (9) , 1051-1063
Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes
Background In universal hepatitis B (HB) vaccination, single vaccine-derived polyclonal anti-HBs antibodies (anti-HBs) need to inhibit infection of HB viruses (HBV) of non-vaccine genotypes. We experimentally addressed this issue. Methods Anti-HBs-positive sera were obtained by vaccination with genotype A- or C-derived HBs antigen (HBsAg, gtA-sera or gtC-sera). Their reactivity to genotype A- and C-derived HBsAg (gtA-Ag and gtC-Ag) was measured by ELISA. The capacity of sera to neutralize HBV was evaluated using an in vitro infection model. Results Of 135 anti-gtA-Ag-reactive gtA-sera, 134 (99.3%) were anti-gtC-Ag-reactive. All (100%) 120 anti-gtC-Ag-reactive gtC-sera were anti-gtA-Ag-reactive. The reactivity to gtA-Ag was strongly correlated with that to gtC-Ag (gtA-sera, ρ = 0.989; gtC-sera, ρ = 0.953; p < 0.01). In gtA-sera (n = 10), anti-HBs to gtA-Ag were less completely absorbed with gtC-Ag (96.4%) than with gtA-Ag (100%, p < 0.05). Similarly, in gtC-sera (n = 10), anti-HBs to gtC-Ag were less completely absorbed with gtA-Ag (96.0%) than with gtC-Ag (100%, p < 0.01). Thus, 3.6 and 4.0% of anti-HBs in gtA-sera and gtC-sera were vaccine genotype HBsAg-specific, respectively. In the neutralization test, gtA-sera (n = 4) and gtC-sera (n = 3) with anti-HBs titers adjusted to 100 mIU/mL equally inhibited genotype C HBV infection (92.8 vs. 95.4%, p = 0.44). However, at 30 mIU/mL, the gtA-sera less effectively inhibited infection than the gtC-sera (60.2 vs. 90.2%, p < 0.05). Conclusions Vaccination with genotype A- or C-derived HBsAg provided polyclonal anti-HBs that sufficiently bound to non-vaccine genotype HBsAg. However, a small portion of anti-HBs were specific to the vaccine genotype HBsAg. High anti-HBs titers would be required to prevent HBV infection of non-vaccine genotypes. UMIN/CTR UMIN000014363.
- 14 July 2015
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 10 (2) , 164-171
Effects of methotrexate and salazosulfapyridine on protein profiles of exosomes derived from a human synovial sarcoma cell line of SW982
Purpose To elucidate effects of salazosulfapyridine (SASP) and methotrexate (MTX), major anti‐rheumatic drugs, on exosomes derived from SW982 of a human synovial sarcoma cell line. Experimental design SW982 was treated with SASP and/or MTX under interleukin‐1β (IL‐1β)‐treated or nontreated conditions. Exosomes were isolated from the culture media, and exosomal proteome was analyzed by 2D‐DIGE. Protein spots whose intensity was significantly altered by the above treatments were identified by MS. Results Two hundred ninety‐four protein spots were detected in the exosome preparations by 2D‐DIGE. Compared to the nontreated cells, SASP‐, MTX‐, and (SASP + MTX)‐treated cells displayed 8, 10, and 21 exosomal protein spots with more than ±2.0‐fold intensity differences (p < 0.05), respectively. Similarly, the IL‐1β‐treated cells displayed 58 exosomal protein spots with more than ±1.5‐fold intensity differences (p < 0.05). In about half of the 58 spots, the IL‐1β‐induced intensity changes were suppressed by simultaneous addition of SASP and/or MTX. Most of the identified proteins were immunity‐ or anti‐oxidation‐related proteins. Conclusions and clinical relevance The SASP and/or MTX treatments altered the protein profiles of exosomes and suppressed the effects of IL‐1β on the exosomal proteome. Exosomes may play roles in the actions of these anti‐rheumatic drugs.
- 14 July 2015
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 10 (2) , 164-171
Effects of methotrexate and salazosulfapyridine on protein profiles of exosomes derived from a human synovial sarcoma cell line of SW982
Purpose To elucidate effects of salazosulfapyridine (SASP) and methotrexate (MTX), major anti‐rheumatic drugs, on exosomes derived from SW982 of a human synovial sarcoma cell line. Experimental design SW982 was treated with SASP and/or MTX under interleukin‐1β (IL‐1β)‐treated or nontreated conditions. Exosomes were isolated from the culture media, and exosomal proteome was analyzed by 2D‐DIGE. Protein spots whose intensity was significantly altered by the above treatments were identified by MS. Results Two hundred ninety‐four protein spots were detected in the exosome preparations by 2D‐DIGE. Compared to the nontreated cells, SASP‐, MTX‐, and (SASP + MTX)‐treated cells displayed 8, 10, and 21 exosomal protein spots with more than ±2.0‐fold intensity differences (p < 0.05), respectively. Similarly, the IL‐1β‐treated cells displayed 58 exosomal protein spots with more than ±1.5‐fold intensity differences (p < 0.05). In about half of the 58 spots, the IL‐1β‐induced intensity changes were suppressed by simultaneous addition of SASP and/or MTX. Most of the identified proteins were immunity‐ or anti‐oxidation‐related proteins. Conclusions and clinical relevance The SASP and/or MTX treatments altered the protein profiles of exosomes and suppressed the effects of IL‐1β on the exosomal proteome. Exosomes may play roles in the actions of these anti‐rheumatic drugs.
- 1 September 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 452 (1) , 85-90
Secretion of inflammatory factors from chondrocytes by layilin signaling
- 1 September 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 452 (1) , 85-90
Secretion of inflammatory factors from chondrocytes by layilin signaling